First Script saw continued decreasing opioid trends across our retail and mail-order programs in 2019, even while overall prescription trends saw a slight upward shift in utilization per claim and cost per claim. Even with these changes, opioids remain the #1 therapeutic class by usage and cost, however, 2019 marked the largest reduction of the last 5 years in the percentage of opioid scripts with greater than or equal to 90 MED. View the video blog here.
Throughout 2026, lawmakers and insurance regulators have increasingly turned their attention to how artificial intelligence (AI) is governed, particularly with decisions affecting consumers. Many proposed AI bills failed to advance this year, but the volume of legislative and regulatory activity sends a clear signal that regulators expect insurers to understand, oversee, and remain accountable for AI-supported activities.
Explore how Apricus streamlined catastrophic claim care coordination for a client. See how one point of contact aligned nursing, mobility equipment and housing.
Discover how Genex's Ticket to Work program helps disability carriers reduce SSA-related risks, support return to work and improve claim outcomes at no added cost.
Mitchell today announced plans to expand its collaboration with Tractable through a proposed, exclusive agreement focused on optimizing the vehicle intake process. By connecting Tractable’s LumaScanner vehicle inspection system with Mitchell’s automated estimating solution, Mitchell Intelligent Estimating, the companies intend to help North American multi-site operators (MSOs) and independent collision repair centers accelerate damage assessment and preliminary estimate creation.
Pharmaceutical products classified as "opportunistic" exploit pricing gaps and regulatory variability to drive disproportionate costs with little-to-no added clinical value. While opportunistic products represent a small fraction of overall prescription volume, their financial impact is significant. This trends analysis identifies where clinical and cost interventions can have the greatest impact.
This section of our drug trends analysis takes a closer look at the current state of opioid utilization and spend across in-network and out-of-network channels. While the overall trajectory is favorable, the data also reveals areas of concern that warrant continued vigilance and targeted intervention.